Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Gastroenterology | Nursing | Oncology | Pharmacy | Surgery | Journal

Back to Journal Articles

Study Supports Chemo After Periampullary Cancer Surgery

Last Updated: July 10, 2012.

 

Benefit only seen after adjusting for prognostic variables, not in primary analysis

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
After adjusting for prognostic variables, patients who receive adjuvant chemotherapy following resection of periampullary adenocarcinomas have improved survival compared with those who receive only observation, according to a study published in the July 11 issue of the Journal of the American Medical Association.

TUESDAY, July 10 (HealthDay News) -- After adjusting for prognostic variables, patients who receive adjuvant chemotherapy following resection of periampullary adenocarcinomas have improved survival compared with those who receive only observation, according to a study published in the July 11 issue of the Journal of the American Medical Association.

To investigate whether adjuvant chemotherapy improves overall survival following resection, John P. Neoptolemos, M.D., from the University of Liverpool in the United Kingdom, and colleagues conducted an open-label, phase 3, randomized controlled trial from July 2000 to May 2008 in 100 centers in Europe, Australia, Japan, and Canada involving 498 patients with periampullary adenocarcinomas. Of these, 297 had ampullary, 96 had bile duct, and 35 had other cancers. Participants were randomized to an observation group (144 patients), to receive folinic acid plus fluorouracil (143 patients), or to receive gemcitabine (141 patients).

The researchers found that 61, 58, and 52 percent of patients in the observation, fluorouracil plus folinic acid, and gemcitabine groups died. Median survival was 35.2 months in the observation group, compared with 43.1 months in the two chemotherapy groups (hazard ratio, 0.86; P = 0.25). Compared with observation, the hazard ratio for chemotherapy was 0.75 (P = 0.03) after adjustment for independent prognostic variables of age, bile duct cancer, poor tumor differentiation, and positive lymph nodes.

"Although this study found support for the use adjuvant chemotherapy to improve survival in patients with periampullary cancers, this effect was modest, indicating a need for further improvements and warranting the testing of combination chemotherapies," the authors write.

Abstract
Full Text

Copyright © 2012 HealthDay. All rights reserved.


Previous: Acadesine Doesn't Improve Outcomes After CABG Next: Tests ID'd for Use in Outcome Assessment of Spinal Stenosis

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.